Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products.Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration (FDA). By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants - in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. In 2014, Dr. Reddy Laboratories was listed among 1200 of India's most trusted brands according to the Brand Trust Report 2014, a study conducted by Trust Research Advisory, a brand analytics company.By 2007, Dr. Reddy's had seven FDA plants producing active pharmaceutical ingredients in India and seven FDA-inspected and ISO 9001 (quality) and ISO 14001 (environmental management) certified plants making patient-ready medications – five of them in India and two in the UK.In 2010, the family-controlled Dr Reddy's denied that it was in talks to sell its generics business in India to US pharmaceutical giant Pfizer, which had been suing the company for alleged patent infringement after Dr Reddy's announced that it intended to produce a generic version of atorvastatin, marketed by Pfizer as Lipitor, an anti-cholesterol medication. Reddy's was already linked to UK pharmaceuticals multinational Glaxo Smithkline. Dr.S.Dr. Dr.Dr.Dr.Dr. Dr.
On Oct 7 and 8, 2024, the US Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) co-hosted a workshop titled "Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products". Stakeholders from the FDA, industry, academia, and contract research organizations convened to discuss strategies for advancing risk assessment methodologies and regulatory frameworks for complex generic products. By assembling experts from various sectors, the workshop explored various available strategies for immunogenicity risk assessment, providing valuable insights to support the development and assessment of generic peptide and oligonucleotide drug products. The discussions fostered a deeper understanding of how these methodologies can inform regulatory decision-making and enhance the development of safer and more effective therapeutics.
The process of ensuring the safety of the food supply is dynamic. Both the possibility of contamination and the effectiveness of safety precautions are impacted by changes in the kinds of food consumed, the geographical origins of food products, and the methods by which these foods are processed. For instance, compared to earlier generations, consumers’ general understanding of safe food preparation and handling techniques has decreased due to a higher reliance on prepackaged convenience foods. Nowadays, consumers depend increasingly on other people to make sure the food they eat is safe. Growing consumption of minimally processed foods and growing imports of fresh products from other nations have resulted from changes in consumer tastes and food processing technologies. This review aims to critically synthesize existing knowledge on microbial risks in food, focusing on their sources, mechanisms of contamination, risk evaluation methodologies, and implementation of food safety measures. Major foodborne pathogens, including Salmonella, Escherichia coli, Listeria monocytogenes, and Norovirus, are discussed alongside factors influencing their survival and transmission. Today Clostridium botulinum, Staphylococcus aureus, and Salmonella spp. remain among the major foodborne pathogens, but during the last two decades food-borne diseases such as shigellosis, listeriosis, campylobacteriosis, and diseases caused by pathogenic strains of Escherichia coli have become increasingly salient. These new concerns necessitate continued investment in research and technology development to improve the safety of the food supply. The review highlights current approaches to microbiological risk assessment, regulatory frameworks, and control strategies, while also addressing emerging challenges such as antimicrobial resistance, biofilms, and ready-to-eat foods. By integrating risk evaluation with practical implementation strategies, this review provides valuable insights for researchers, regulators, and food industry stakeholders seeking to strengthen food safety systems and reduce the burden of foodborne diseases.
The gut-brain-heart axis represents a dynamic interplay between the gut microbiota, cognitive function, and cardiovascular health, with profound implications for understanding and managing chronic diseases. In dysbiosis, a disruption in microbial balance contributes to neuro-inflammation, mood disorders, neurodegenerative diseases, and cardiovascular conditions such as atherosclerosis and hypertension. To date, researchers explored different mechanism through which gut microbial communities influence the activities of brain and heart. In order to understand these mechanisms summative, in this review, we focused on key communication pathways between microbiota-gut-brain-heart, such as vagus nerve, gut-derived metabolites, and systemic inflammation. Furthermore, the review discusses the bidirectional nature of these relationships, where cardiovascular and cognitive health mutually influence one another. Therapeutic interventions, including probiotics, dietary modifications, biotechnological approach and lifestyle changes are evaluated for their potential to modulate the gut-brain-heart axis and improve health outcomes. Despite significant advances, challenges remain in understanding the complex interactions within this axis. Future research directions emphasize personalized medicine approaches and the potential of microbiome-targeted therapies to revolutionize the prevention and treatment of cognitive and cardiovascular disorders.
Objectives: The objective of the study is to evaluate the dermatological safety, tolerability, and hypoallergenic potential of Venusia Cleanser using the human repeat insult patch test (HRIPT). Materials and Methods: A single-center, evaluator-blinded HRIPT was conducted on 220 healthy adults aged 18–65 years, including participants with sensitive skin identified through the lactic acid sting test. The test product (1% diluted Venusia Cleanser) and a negative control (0.9% isotonic saline) were applied occlusively on the participant’s back in three phases: Induction (nine 24 h applications), rest (14 days), and challenge (single 24 h application). Skin reactions were assessed using the Draize scale during induction and the International Contact Dermatitis Research Group scale during challenge. Safety and sensitization potential were evaluated qualitatively. Results: Of 220 participants recruited, 218 participants completed the study. 36% ( n = 78) were confirmed to have sensitive skin. During the induction phase, the mean cumulative irritation score for Venusia Cleanser was 0.08, significantly below the threshold of 2.0, which defines non-irritant status according to Bureau of Indian Standards - Indian Standard 4011: 2018 Methods of Test for Safety Evaluation of Cosmetics (Third Revision) guidelines. Throughout the challenge phase, no strong positive or irritant reactions were observed at any time point. Only a few participants experienced transient, minor, doubtful reactions at 48 h, which resolved quickly without any lasting effects. No adverse events or safety concerns were reported during the entire study period. Conclusion: Venusia Cleanser demonstrated a non-irritant and hypoallergenic profile under HRIPT conditions, supporting its safe repeated use, including in individuals with sensitive skin. Being a single-center study, the findings may limit the generalizability of the results to broader and more diverse populations.